CE Mark approval in September 2011 and to date over 100 commercial implants have been performed. The device is composed of a porcine biologic valve attached to a self-expanding nitinol stent designed for simple 2-step implantation and characterized by controlled positioning, self-seating in the native annulus resulting in a negligible paravalvular leak rate. The device was tested in patients at high-risk for mortality with open surgical repair. Methods: Ninety (90) patients (femaleϭ69%) with severe aortic stenosis, a mean age of 83.4 Ϯ 4.1 years, all presenting with NYHA Functional Class III or IV and a mean STS Score of 7.9 Ϯ 4.6 were enrolled in two studies in Germany at 6 centers. Patients are clinically followed at 7 and 30 days, at 6 and 12 months, and annually thereafter out to 5 years post-implant. The device was successfully implanted in 94.4% of patients (nϭ85) with a pacemaker implantation rate of 11.1% (nϭ10). Results: At 12 months the survival rate is 81.1% (nϭ73), the stroke rate is 4.4% (nϭ4), with no further re-intervention required on the implanted device since procedure. Of the returning patients, 87% presented with NYHA Functional Class I/II. The mean gradient at 6 months is 10.3 Ϯ 5.2 mmHg, the mean EOA is 1.5 Ϯ 0.4 cm2 and 77.3% of returning patients suffered no paravalvular leak, 21.2% exhibit mild paravalvular leak (ϩ1) and only 1 patient possesses a moderate paravalvular leak (ϩ2). Conclusions: These data confirm the safety profile at one year of this 2nd Generation TAVI system. We will report the full 12 months results of this multi-center, nonrandomized study of this transapically-placed transcatheter aortic valve at TCT 2012.
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Background:
The Edwards SAPIEN valve has been FDA-approved with its Retroflex delivery system for retrograde transfemoral (TF) treatment of inoperable patients with severe aortic stenosis, and is the only device clinically available for transcatheter aortic valve replacement (TAVR) in the United States (US). Because of insufficient iliofemoral vascular access, many patients are excluded from the TF approach. We explored transaortic (TAO) TAVR as an alternate access strategy for these patients. Methods: Twenty-five consecutive patients underwent TAO TAVR between January and April, 2012 at our site. All had symptomatic severe aortic stenosis, were inoperable, and had inadequate vascular access for TF delivery. Through a small upper sternotomy and direct insertion of the sheath into the ascending aorta, we delivered the valve using the Retroflex catheter. Procedural and 30-day outcomes were retrospectively compared with the first 25 patients treated by transapical (TA) access in our program. Results: TAO TAVR was successfully performed in all patients. One perioperative death occurred, which was unrelated to the TAO approach. No other cardiovascular death was reported within 30 days. Compared with TA access, TAO TAVR had a similar all-cause mortality rate at 30 days, and was associated lower incidence of bleeding events, as well as shorter ICU length of stay. Conclusions: TAVR via the TAO approach, using the only commercially-available device in the US, is technically feasible and is associated with favorable outcomes in inoperable patients with severe aortic stenosis who are not candidates for TF access. In these patients, the TAO approach expands the current alternative options for TAVR access sites. Efforts directed towards enhancing the technologies and techniques associated with TAO TAVR should further improve the efficacy and safety of this procedure. Background: Transcatheter aortic valve replacement is recommended in inoperable patients with severe, symptomatic aortic stenosis (AS), and is an accepted alternative to surgical AVR in high risk patients. However, increased stroke, bleeding, vascular complications and aortic regurgitation (AR) rates may adversely affect outcomes. The repositionable and fully retrievable Lotus Valve is designed to facilitate accurate positioning and minimize paravalvular leakage. Methods: REPRISE I is a prospective, single-arm, 3-center feasibility study to assess acute safety and performance in symptomatic patients with severe AS at high surgical risk. The primary endpoint was clinical procedural success (successful implantation without in-hospital major adverse cardiovascular and cerebrovascular events to discharge or 7 days, whichever came first). Results: The Lotus Valve was implanted in 11 patients with mean STS and logistic euroSCOREs of 4.9Ϯ2.5% and 9.5Ϯ4.4%, respectively, and high surgical risk due to comorbidities/frailty (cognitive dysfunction in 5/11, gait speed Ն6s in 9/11, grip strength Յ18kg in 7/11). At baseline 6 patients were NYHA Class II and 5 were Class III. Clinical procedural success was achieved in 9/11. One patient experienced a major ischemic stroke (MRSϭ3 at discharge; final 90-day adjudication pending). A second had a mean post-procedure gradient of 22mmHg (above the 20mmHg VARC threshold) although the valve was functioning well (post-procedure AVA 1.6cm2). Partial resheathing was performed in 4/4 patients; none required full retrieval. Mean aortic gradient was 53.9Ϯ20.9mmHg at baseline and 13.7Ϯ3.7mmHg at discharge. Mean AVA was 0.7Ϯ0.2cm 2 at baseline and 1.5Ϯ0.2cm 2 at discharge. Paravalvular AR was mild in 2 patients, trivial in 1, absent in 8. Conduction disturbance requiring a new pacemaker occurred in 4 patients (2 with complete AV block). There were no deaths or MIs through 7 days. Conclusions: Early feasibility results suggest that the Lotus Valve can be positioned precisely and successfully with virtually no AR and low clinical event rates through discharge, supporting further study in a larger, more rigorous trial. Three-month data will be presented for the first time at TCT 2012. 
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